Top Markets
#1 Purr Purr +64.03%
#2 Pons Pons +54.56%
#3 Smilek to the Bank Smilek to the Bank +50.56%
#4 TENDIES TENDIES +40.15%
#5 Non-Playable Coin Non-Playable Coin +34.25%
#6 Cash Cat Cash Cat +32.21%
#7 Morpho Morpho +26.64%
#8 Kinetiq Kinetiq +23.90%
#9 StonkBroker StonkBroker +22.07%
#10 ApeX ApeX +21.54%
Coin of the day
Purr Purr
Настройки
Язык
Pусский
Валюта
USD
Тема
Coya Therapeutics, Inc. Coya Therapeutics, Inc.

Coya Therapeutics, Inc.

COYA
Ранг среди акций #21166
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on... Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutic agents that fine-tune the function of regulatory T cells (Tregs). Its therapeutic pipeline leverages diverse approaches, including biologics designed to enhance Treg activity, Treg-derived exosomes, and personalized autologous Treg cell therapies. Among its lead candidates is COYA 101, an autologous regulatory T-cell product that has successfully completed Phase 2a clinical trials for treating Amyotrophic Lateral Sclerosis (ALS). Moving towards Investigational New Drug (IND) applications are two key candidates: COYA 301 and COYA 302. COYA 301 is a Treg-enhancing biologic aimed at treating Frontotemporal Dementia. Meanwhile, COYA 302 is a dual-action biologic combination, suitable for subcutaneous or intravenous delivery, engineered to not only boost Treg function but also to diminish harmful T effector cell activity and activated macrophages in neurodegenerative and autoimmune disorders. Additionally, Coya has earlier-stage programs, including COYA 201, an allogeneic (off-the-shelf) Treg exosome candidate in preclinical development for a range of neurodegenerative, autoimmune, and metabolic conditions. Its pipeline also features COYA 206, an antigen-directed Treg-derived exosome product, currently in the discovery phase. Established in 2020, Coya Therapeutics maintains its headquarters in Houston, Texas.
Цена акции
$4.83
Последняя синхронизация: 2026-08-21
Рыночная капитализация
$113.30M
Изменение (1 день)
-0.62%
Изменение (1 год)
-29.59%
Страна
US
Торговля Coya Therapeutics, Inc. (COYA)

Категория

Healthcare
Прибыль Coya Therapeutics, Inc. (COYA)
Прибыль на 2026 TTM: 0
Согласно последним финансовым отчетам Coya Therapeutics, Inc., текущая прибыль компании составляет 0. В 2026 году компания получила прибыль 0, равна прибыли за 2026, которая составила 0. Отображаемая прибыль на этой странице — это прибыль до уплаты процентов и налогов, или просто EBIT.
История прибыли компании Coya Therapeutics, Inc. с 2026 по 2026
Прибыль в конце каждого года
Год Прибыль Изменить
Недостаточно данных для указанных дат.
Прибыль схожих компаний или конкурентов
Компания Прибыль Разница в прибыли Страна
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH